Placebo for ABBV-142
Sponsors
AbbVie Deutschland GmbH & Co. KG, AbbVie
Conditions
Idiopathic Pulmonary Fibrosis
Phase 2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
RecruitingNCT07230288
Start: 2026-01-23End: 2029-09-01Target: 165Updated: 2026-09-03
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis
Not yet recruitingCTIS2024-518013-25-00
Target: 17Updated: 2026-03-11